Brought to you by 
Advaxis enters $540mm immunotherapy deal with Amgen
10 Nov 2021
Executive Summary
Advaxis Inc. licensed Amgen Inc. exclusive worldwide rights to develop and sell its preclinical cancer immunotherapy ADXSNEO, the first project to arise from Advaxis' new MINE (MyImmunotherapy Neo-Epitopes) program for customizable cancer treatments.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Advaxis enters $540mm immunotherapy deal with Amgen
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice